Balance after chemotherapy (BAC)
Research type
Research Study
Full title
A prospective longitudinal study of vestibular toxicity associated with cisplatin in survivors of cancer
IRAS ID
242739
Contact name
Pattarawadee Prayuenyong
Contact email
Sponsor organisation
University of Nottingham
Duration of Study in the UK
2 years, 0 months, 0 days
Research summary
Cisplatin is an effective antineoplastic treatment for a variety of human cancers. Irreversible hearing loss was reported in 40-80% of patients treated with cisplatin; however, clinical research data on vestibular toxicity is very sparse. Vestibular organs of the inner ear play an important role in human balance system; consequently, exploration of vestibular side effects of cisplatin is worth conducting in this vulnerable group of patients. The study objective is to evaluate incidence and impacts of adverse effects related to vestibular functions before and after cisplatin chemotherapy. In this study, we will recruit testicular or gynaecologic cancer patients aged 18-60 years old who will receive cisplatin for curative treatment at the Oncology Clinic, City Hospital, Nottingham. Theses results will enable us to inform future clinical practice and create better holistic patient care.
REC name
East Midlands - Derby Research Ethics Committee
REC reference
18/EM/0225
Date of REC Opinion
31 Aug 2018
REC opinion
Further Information Favourable Opinion